COAGULOPATHY AND CORONAVIRUS DISEASE 2019
Abstract
Interest in coronavirus disease 2019 (COVID-19) in the world of science is constant. Pathogenesis is the subject of many studies, and coagulopathy occupies an important place in research. In our study, blood samples were collected from 131 patients treated for SARS-CoV-2 infection in University Clinical Center Kragujevac. Blood was sampled on the day of admission, and the disease course was monitored. We concluded that our participants do not meet the criteria for disseminated intravascular coagulation (DIC). We showed the statistical significance of platelet count, prothrombin time value and DIC score concerning the form and outcome of the disease. Patients with a critical form of the disease, as well as those who died, had significantly lower values of the number of platelets and significantly higher values of the DIC score.
References
A practical guide to haemostasis. ISTH DIC Scoring Algorithm. Available at: https://practical-haemostasis.com/. Accessed on December 1,2022.
Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med 2020;383(2):120-8. [CrossRef] [PubMed]
Al-Saadi EAKD, Abdulnabi MA. Hematological changes associated with COVID-19 infection. J Clin Lab Anal 2022;36(1):e24064. [CrossRef] [PubMed]
Anwar N, Tashfeen S, Akhtar F, Noor A, Khan SA, Omair A. Can disseminated intravascular coagulation scores predict mortality in COVID-19 patients? J Taibah Univ Med Sci 2021;16(4):596-604. [CrossRef] [PubMed]
Asakura H, Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int J Hematol 2021;113(1):45-57. [CrossRef] [PubMed]
Barale C, Melchionda E, Morotti A, Russo I. Prothrombotic Phenotype in COVID-19: Focus on Platelets. Int J Mol Sci 2021;22(24):13638. [CrossRef] [PubMed]
Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis 2020;20(10):1135-40. [CrossRef] [PubMed]
Comer SP, Cullivan S, Szklanna PB, Weiss L, Cullen S, Kelliher S, et al. COVID-19 induces a hyperactive phenotype in circulating platelets. PLoS Biol 2021;19(2):e3001109. [CrossRef] [PubMed]
Flaumenhaft R, Enjyoji K, Schmaier AA. Vasculopathy in COVID-19. Blood 2022;140(3):222-35. [CrossRef] [PubMed]
Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med 2020;8(7):681-6. [CrossRef] [PubMed]
Gerber GF, Chaturvedi S. How to recognize and manage COVID-19-associated coagulopathy. Hematology Am Soc Hematol Educ Program 2021;2021(1):614-20. [CrossRef] [PubMed]
Hadid T, Kafri Z, Al-Katib A. Coagulation and anticoagulation in COVID-19. Blood Rev 2021;47:100761. [CrossRef] [PubMed]
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506. [CrossRef] [PubMed]
Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 2020;8(6):e46-e47. [CrossRef] [PubMed]
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033-4. [CrossRef] [PubMed]
Nasif WA, El-Moursy Ali AS, Hasan Mukhtar M, Alhuzali AMH, Yahya Alnashri YA, Ahmed Gadah ZI, et al. Elucidating the Correlation of D-Dimer Levels with COVID-19 Severity: A Scoping Review. Anemia 2022;2022:9104209. [CrossRef] [PubMed]
Portier I, Campbell RA, Denorme F. Mechanisms of immunothrombosis in COVID-19. Curr Opin Hematol 2021;28(6):445-53. [CrossRef] [PubMed]
Qu R, Ling Y, Zhang YH, Wei LY, Chen X, Li XM, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol 2020;92(9):1533-41. [CrossRef] [PubMed]
Teimury A, Khameneh MT, Khaledi EM. Major coagulation disorders and parameters in COVID-19 patients. Eur J Med Res 2022;27(1):25. [CrossRef] [PubMed]
Thilagar B, Beidoun M, Rhoades R, Kaatz S. COVID-19 and thrombosis: searching for evidence. Hematology Am Soc Hematol Educ Program 2021;2021(1):621-7. [CrossRef] [PubMed]
Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol 2020;108(1):17-41. [CrossRef] [PubMed]
Weiss SL, Peters MJ, Alhazzani W, Agus MSD, Flori HR, Inwald DP, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Intensive Care Med 2020;46(Suppl 1):10-67. [CrossRef] [PubMed]
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020;324(8):782-93. [CrossRef] [PubMed]
World Health Organization. Therapeutics and COVID-19: living guideline. 2022 September. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV therapeutics-2022.5, Accessed December 1,2022
